"Antitubercular Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy.
| Descriptor ID |
D000995
|
| MeSH Number(s) |
D27.505.954.122.085.255
|
| Concept/Terms |
Antitubercular Agents- Antitubercular Agents
- Agents, Antitubercular
- Antitubercular Drugs
- Drugs, Antitubercular
- Tuberculostatic Agents
- Agents, Tuberculostatic
|
Below are MeSH descriptors whose meaning is more general than "Antitubercular Agents".
Below are MeSH descriptors whose meaning is more specific than "Antitubercular Agents".
This graph shows the total number of publications written about "Antitubercular Agents" by people in this website by year, and whether "Antitubercular Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2003 | 1 | 1 | 2 |
| 2006 | 3 | 0 | 3 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 1 | 2 |
| 2010 | 3 | 1 | 4 |
| 2011 | 2 | 1 | 3 |
| 2012 | 2 | 2 | 4 |
| 2013 | 2 | 0 | 2 |
| 2014 | 1 | 1 | 2 |
| 2015 | 5 | 2 | 7 |
| 2017 | 3 | 0 | 3 |
| 2018 | 1 | 3 | 4 |
| 2019 | 1 | 1 | 2 |
| 2020 | 1 | 1 | 2 |
| 2021 | 0 | 1 | 1 |
| 2022 | 1 | 1 | 2 |
| 2023 | 0 | 2 | 2 |
| 2024 | 1 | 0 | 1 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antitubercular Agents" by people in Profiles.
-
Different chemical scaffolds bind to L-phe site in Mycobacterium tuberculosis Phe-tRNA synthetase. Eur J Med Chem. 2025 Apr 05; 287:117335.
-
A host-directed oxadiazole compound potentiates antituberculosis treatment via zinc poisoning in human macrophages and in a mouse model of infection. PLoS Biol. 2024 Apr; 22(4):e3002259.
-
Mycobacterium tuberculosis carrying the rifampicin drug-resistance-conferring rpoB mutation H445Y is associated with suppressed immunity through type I interferons. mBio. 2023 Oct 31; 14(5):e0094623.
-
Rifampicin drug resistance and host immunity in tuberculosis: more than meets the eye. Trends Immunol. 2023 09; 44(9):712-723.
-
Sex Differences in Active Pulmonary Tuberculosis Outcomes in Mali, West Africa. Am J Trop Med Hyg. 2022 08 17; 107(2):433-440.
-
Accurate and rapid prediction of tuberculosis drug resistance from genome sequence data using traditional machine learning algorithms and CNN. Sci Rep. 2022 02 14; 12(1):2427.
-
Longitudinal Dynamics of a Blood Transcriptomic Signature of Tuberculosis. Am J Respir Crit Care Med. 2021 12 15; 204(12):1463-1472.
-
Development of small-molecule inhibitors of fatty acyl-AMP and fatty acyl-CoA ligases in Mycobacterium tuberculosis. Eur J Med Chem. 2020 Sep 01; 201:112408.
-
Immunometabolism during Mycobacterium tuberculosis Infection. Trends Microbiol. 2020 10; 28(10):832-850.
-
Cold Case: Mystery in the Midwest of Metastatic Tuberculous Abscesses. Am J Med. 2020 03; 133(3):301-303.